You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥(02137.HK)超額配股權獲部份行使 股價急漲16%破頂
阿思達克 08-06 11:51
上月13日才以每股22.25元上市的騰盛博藥-B(02137.HK)超額配股權獲部份行使,該股扭三連跌,今早升破本周一盤中所創上市高位26.8元,最高見28.65元,現報28.6元,急漲近16%,成交增至421萬股,涉資1.188億元。 騰盛博藥公布,聯席全球協調人昨天(5日)以每股22.25元部份行使超額配股權,涉共1,375.3萬股,佔發售總數12.33%,額外所得淨額約2.94億元。此外,有關全球發售的穩定價格期已於昨天結束。期間,穩定價格經辦人摩根士丹利亞洲在市場購買合共298.4萬股,每股作價介乎19.22-22.25元,最後一次購買日期7月28日,價格22.25元。 騰盛是一家位於中國及美國仍未有盈利生物科技公司,致力於促進中國及全球就重大傳染病如乙型肝炎病毒(HBV)、人類免疫缺陷病毒(HIV)、多重耐藥(MDR)或廣泛耐藥性(XDR)革蘭氏陰性菌感染,以及其他具有重大公共衛生負擔的疾病如中樞神經系統(CNS)疾病的療法。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account